Cite
APA Citation
Perez, C., Wesolowski, R., Wilky, B., Feliu, W. O., Zhang, H., Shapiro, I., Wijatyk, A., Kaleta, R., & Trent, J. (n.d.). 256 Single-agent zalifrelimab (anti-CTLA-4) shows clinical benefit in rare tumors – case report from phase 2 study (NCT03104699). Journal for immunotherapy of cancer, 8, A155. http://access.bl.uk/ark:/81055/vdc_100144725746.0x000005